Pre-conference Workshop
Future proofing your deals in a more volatile world
Join transactional attorneys from Ropes & Gray for an engaging panel on how to structure cross-border strategic life sciences deals that are built to last.
In today’s climate of shifting regulations, evolving enforcement priorities, and heightened geopolitical tension, “future-proofing” your transactions is more critical than ever. Drawing on deep experience advising global biopharma and medtech companies, Hannah England and Matt Byron will explore practical strategies to safeguard value—ranging from change-in-law protections and adaptive regulatory covenants to risk allocation mechanisms that anticipate sanctions, trade controls, and supply chain disruption.
Attendees will gain actionable insights into drafting resilient collaboration, licensing, and M&A agreements that can withstand uncertainty while preserving strategic flexibility. Whether you are expanding into new markets or partnering across jurisdictions, this session will equip you with the tools to structure deals that endure.
Pre-conference workshop speakers
-
Hannah England Ropes & GrayHannah EnglandPartner, Life Sciences Licensing & Collaborations
Bio
Hannah advises a wide range of public and private companies, investors, and institutions in the life sciences industry on strategic transactions that are of critical strategic importance, with particular focus in licensing and collaboration transactions, asset acquisitions and divestitures, joint ventures, R&D financing arrangements, royalty monetizations, strategic manufacturing agreements, and co-commercialization arrangements. Hannah’s deal sheet illustrates the depth of her experience, and she has also been recognized by numerous publications and ranking organizations for her work in the field, including as the Life Sciences licensing and collaboration attorney of the year by LMG Life Sciences, as the practitioner of the year for IP transactions by Managing Intellectual Property Americas, and as a Life Sciences MVP by Law360.
Hannah’s clients include all manner of players in the life sciences industry and include global biotechnology and pharmaceutical companies such as Pfizer, Takeda, and Boehringer Ingelheim, smaller biotechnology pioneers such as Blueprint Medicines, Lian Bio, iTeos Therapeutics, Kiniksa Therapeutics, Shape Therapeutics, Sana Biotechnology, and Sarepta Therapeutics, royalty purchasers such as Royalty Pharma, academic institutions such as The Broad Institute, venture funds, private equity funds, and securities underwriters. -
Emily Oldshue Ropes & GrayEmily OldshuePartner, Life Sciences M&A at Ropes & Gray
Bio
Emily Oldshue brings a leading transactional lawyer's perspective to mergers and acquisitions. Her insight into how to navigate challenging business issues and complex transactions has made her a trusted advisor for a diverse base of public and private companies. In M&A, clients benefit from the breadth of Emily’s experience, which includes significant cross-border work, carveouts, spin-offs, majority and minority investments, joint ventures, divestitures, bolt-ons and a variety of other complex strategic transactions in addition to regular-way public and private M&A. In addition to her transactional work, Emily counsels clients on ongoing corporate governance matters.